McElhenny Sheffield Capital Management LLC Sells 6,533 Shares of Abbott Laboratories $ABT

McElhenny Sheffield Capital Management LLC cut its stake in shares of Abbott Laboratories (NYSE:ABT) by 34.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,657 shares of the healthcare product maker’s stock after selling 6,533 shares during the period. Abbott Laboratories accounts for 0.4% of McElhenny Sheffield Capital Management LLC’s holdings, making the stock its 15th largest position. McElhenny Sheffield Capital Management LLC’s holdings in Abbott Laboratories were worth $1,586,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Charles Schwab Trust Co lifted its position in Abbott Laboratories by 109.8% during the third quarter. Charles Schwab Trust Co now owns 29,412 shares of the healthcare product maker’s stock worth $3,939,000 after acquiring an additional 15,394 shares during the last quarter. Danica Pension Livsforsikringsaktieselskab acquired a new stake in Abbott Laboratories during the third quarter worth approximately $185,640,000. Asset Management One Co. Ltd. lifted its position in Abbott Laboratories by 2.4% during the third quarter. Asset Management One Co. Ltd. now owns 858,834 shares of the healthcare product maker’s stock worth $115,032,000 after acquiring an additional 19,966 shares during the last quarter. Nordea Investment Management AB lifted its position in Abbott Laboratories by 6.1% during the third quarter. Nordea Investment Management AB now owns 329,430 shares of the healthcare product maker’s stock worth $43,785,000 after acquiring an additional 18,974 shares during the last quarter. Finally, AE Wealth Management LLC lifted its position in Abbott Laboratories by 20.8% during the third quarter. AE Wealth Management LLC now owns 65,504 shares of the healthcare product maker’s stock worth $8,774,000 after acquiring an additional 11,264 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Barclays raised its price target on ABT to $144 and keeps an “overweight” view, a bullish signal that likely helped buying interest. Abbott Laboratories price target raised by Barclays
• Positive Sentiment: Coverage highlighting Abbott as a “dividend king on sale” (value/dividend investors) increases interest from income-focused buyers given its long track record of payout consistency. A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?
• Neutral Sentiment: Several sell‑side analysts remain constructive (maintaining buy/outperform ratings) but trimmed targets modestly (Evercore to $134 from $138; BTIG similar), which is mixed news — keeps analyst support but reduces implied upside. Evercore ISI and BTIG Lower Abbott (ABT) Price Targets, Maintain Positive Ratings
• Neutral Sentiment: Analysts and media note the stock’s recent underperformance versus the broader market even as it edges up intraday — an important context for short‑term momentum traders. Abbott Laboratories stock rises Wednesday, still underperforms market
• Negative Sentiment: Goldman Sachs cut its price target sharply to $121 from $140 (still a “buy”), a downgrade in expectation that can pressure sentiment and cap near‑term gains. Goldman Sachs adjusts price target on Abbott Laboratories to $121 from $140; maintains buy rating
• Negative Sentiment: Analyses flag recent share weakness (down materially over the past 1–3 months) and fading momentum; fundamental concerns include a modest revenue shortfall in the last quarter despite EPS in line and only modest FY guidance — reasons some investors remain cautious. Assessing Abbott Laboratories (ABT) Valuation After Recent Share Price Weakness

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on ABT shares. Citigroup cut their price objective on shares of Abbott Laboratories from $140.00 to $136.00 and set a “buy” rating for the company in a research report on Wednesday, March 11th. Evercore dropped their price target on shares of Abbott Laboratories from $138.00 to $134.00 and set an “outperform” rating for the company in a research report on Monday. BTIG Research dropped their price target on shares of Abbott Laboratories from $140.00 to $131.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. Barclays lifted their price target on shares of Abbott Laboratories from $142.00 to $144.00 and gave the company an “overweight” rating in a research report on Wednesday. Finally, Oppenheimer dropped their price target on shares of Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $134.58.

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, VP John A. Jr. Mccoy sold 585 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $67,614.30. Following the completion of the transaction, the vice president directly owned 24,628 shares in the company, valued at $2,846,504.24. The trade was a 2.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Mary K. Moreland sold 613 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $70,850.54. Following the transaction, the executive vice president owned 104,291 shares of the company’s stock, valued at approximately $12,053,953.78. This represents a 0.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 3,055 shares of company stock valued at $353,097. 0.46% of the stock is currently owned by insiders.

Abbott Laboratories Stock Up 1.8%

Shares of ABT opened at $103.70 on Thursday. Abbott Laboratories has a one year low of $100.88 and a one year high of $139.06. The company has a market cap of $180.61 billion, a P/E ratio of 27.88, a P/E/G ratio of 1.64 and a beta of 0.79. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18. The firm has a 50 day simple moving average of $109.17 and a two-hundred day simple moving average of $120.35.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting the consensus estimate of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The business had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. During the same period in the previous year, the business earned $1.34 earnings per share. The company’s revenue was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Research analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 2.4%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s payout ratio is currently 67.74%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.